This inventor holds 1 USPTO granted patent. Top assignee: Quest Pharmatech, Inc.. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Michael Hollingsworth: Innovator in Monoclonal Antibody Research
Introduction
Michael Hollingsworth is a notable inventor based in Omaha, NE (US). He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on innovative solutions for cancer treatment.
Latest Patents
Hollingsworth holds a patent for the MUC16 monoclonal antibody and its uses. This patent describes an antibody or an antigen-binding fragment that binds to the O-glycan mucin-type glycoprotein MUC16. The invention includes three variable heavy domain complementarity determining regions (CDR H1, H2, and H3), and three variable light domain CDR (CDR L1, L2, and L3). Additionally, the patent relates to pharmaceutical compositions, nucleic acid vectors, and methods for inhibiting tumor growth of tumors expressing MUC16.
Career Highlights
Michael Hollingsworth is associated with Quest Pharmatech, Inc., where he continues to advance his research in monoclonal antibodies. His work has the potential to impact cancer therapies significantly.
Collaborations
Hollingsworth collaborates with notable colleagues such as Ragupathy Madiyalakan and Prakash Radhakrishnan. Their combined expertise enhances the research and development efforts in their field.
Conclusion
Michael Hollingsworth is a prominent figure in the field of monoclonal antibody research, with a focus on innovative cancer treatments. His contributions through patents and collaborations are paving the way for advancements in biotechnology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile